2024-09-012025-08-312025-08-31false14294023MONET BEAUTY CLINIC LIMITED2026-05-2786210falseiso4217:GBPxbrli:pure142940232024-08-31142940232025-08-31142940232024-09-012025-08-31142940232023-08-31142940232024-08-31142940232023-09-012024-08-3114294023bus:SmallEntities2024-09-012025-08-3114294023bus:AuditExempt-NoAccountantsReport2024-09-012025-08-3114294023bus:FullAccounts2024-09-012025-08-3114294023bus:PrivateLimitedCompanyLtd2024-09-012025-08-3114294023core:WithinOneYear2025-08-3114294023core:AfterOneYear2025-08-3114294023core:WithinOneYear2024-08-3114294023core:AfterOneYear2024-08-3114294023core:ShareCapital2025-08-3114294023core:SharePremium2025-08-3114294023core:RevaluationReserve2025-08-3114294023core:OtherReservesSubtotal2025-08-3114294023core:RetainedEarningsAccumulatedLosses2025-08-3114294023core:ShareCapital2024-08-3114294023core:SharePremium2024-08-3114294023core:RevaluationReserve2024-08-3114294023core:OtherReservesSubtotal2024-08-3114294023core:RetainedEarningsAccumulatedLosses2024-08-3114294023core:LandBuildings2025-08-3114294023core:PlantMachinery2025-08-3114294023core:Vehicles2025-08-3114294023core:FurnitureFittings2025-08-3114294023core:OfficeEquipment2025-08-3114294023core:NetGoodwill2025-08-3114294023core:IntangibleAssetsOtherThanGoodwill2025-08-3114294023core:ListedExchangeTraded2025-08-3114294023core:UnlistedNon-exchangeTraded2025-08-3114294023core:LandBuildings2024-08-3114294023core:PlantMachinery2024-08-3114294023core:Vehicles2024-08-3114294023core:FurnitureFittings2024-08-3114294023core:OfficeEquipment2024-08-3114294023core:NetGoodwill2024-08-3114294023core:IntangibleAssetsOtherThanGoodwill2024-08-3114294023core:ListedExchangeTraded2024-08-3114294023core:UnlistedNon-exchangeTraded2024-08-3114294023core:LandBuildings2024-09-012025-08-3114294023core:PlantMachinery2024-09-012025-08-3114294023core:Vehicles2024-09-012025-08-3114294023core:FurnitureFittings2024-09-012025-08-3114294023core:OfficeEquipment2024-09-012025-08-3114294023core:NetGoodwill2024-09-012025-08-3114294023core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3114294023core:ListedExchangeTraded2024-09-012025-08-3114294023core:UnlistedNon-exchangeTraded2024-09-012025-08-3114294023core:MoreThanFiveYears2024-09-012025-08-3114294023core:Non-currentFinancialInstruments2025-08-3114294023core:Non-currentFinancialInstruments2024-08-3114294023dpl:CostSales2024-09-012025-08-3114294023dpl:DistributionCosts2024-09-012025-08-3114294023core:LandBuildings2024-09-012025-08-3114294023core:PlantMachinery2024-09-012025-08-3114294023core:Vehicles2024-09-012025-08-3114294023core:FurnitureFittings2024-09-012025-08-3114294023core:OfficeEquipment2024-09-012025-08-3114294023dpl:AdministrativeExpenses2024-09-012025-08-3114294023core:NetGoodwill2024-09-012025-08-3114294023core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3114294023dpl:GroupUndertakings2024-09-012025-08-3114294023dpl:ParticipatingInterests2024-09-012025-08-3114294023dpl:GroupUndertakingscore:ListedExchangeTraded2024-09-012025-08-3114294023core:ListedExchangeTraded2024-09-012025-08-3114294023dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-09-012025-08-3114294023core:UnlistedNon-exchangeTraded2024-09-012025-08-3114294023dpl:CostSales2023-09-012024-08-3114294023dpl:DistributionCosts2023-09-012024-08-3114294023core:LandBuildings2023-09-012024-08-3114294023core:PlantMachinery2023-09-012024-08-3114294023core:Vehicles2023-09-012024-08-3114294023core:FurnitureFittings2023-09-012024-08-3114294023core:OfficeEquipment2023-09-012024-08-3114294023dpl:AdministrativeExpenses2023-09-012024-08-3114294023core:NetGoodwill2023-09-012024-08-3114294023core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3114294023dpl:GroupUndertakings2023-09-012024-08-3114294023dpl:ParticipatingInterests2023-09-012024-08-3114294023dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3114294023core:ListedExchangeTraded2023-09-012024-08-3114294023dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3114294023core:UnlistedNon-exchangeTraded2023-09-012024-08-3114294023core:NetGoodwill2025-08-3114294023core:IntangibleAssetsOtherThanGoodwill2025-08-3114294023core:LandBuildings2025-08-3114294023core:PlantMachinery2025-08-3114294023core:Vehicles2025-08-3114294023core:FurnitureFittings2025-08-3114294023core:OfficeEquipment2025-08-3114294023core:AfterOneYear2025-08-3114294023core:WithinOneYear2025-08-3114294023core:ListedExchangeTraded2025-08-3114294023core:UnlistedNon-exchangeTraded2025-08-3114294023core:ShareCapital2025-08-3114294023core:SharePremium2025-08-3114294023core:RevaluationReserve2025-08-3114294023core:OtherReservesSubtotal2025-08-3114294023core:RetainedEarningsAccumulatedLosses2025-08-3114294023core:NetGoodwill2024-08-3114294023core:IntangibleAssetsOtherThanGoodwill2024-08-3114294023core:LandBuildings2024-08-3114294023core:PlantMachinery2024-08-3114294023core:Vehicles2024-08-3114294023core:FurnitureFittings2024-08-3114294023core:OfficeEquipment2024-08-3114294023core:AfterOneYear2024-08-3114294023core:WithinOneYear2024-08-3114294023core:ListedExchangeTraded2024-08-3114294023core:UnlistedNon-exchangeTraded2024-08-3114294023core:ShareCapital2024-08-3114294023core:SharePremium2024-08-3114294023core:RevaluationReserve2024-08-3114294023core:OtherReservesSubtotal2024-08-3114294023core:RetainedEarningsAccumulatedLosses2024-08-3114294023core:NetGoodwill2023-08-3114294023core:IntangibleAssetsOtherThanGoodwill2023-08-3114294023core:LandBuildings2023-08-3114294023core:PlantMachinery2023-08-3114294023core:Vehicles2023-08-3114294023core:FurnitureFittings2023-08-3114294023core:OfficeEquipment2023-08-3114294023core:AfterOneYear2023-08-3114294023core:WithinOneYear2023-08-3114294023core:ListedExchangeTraded2023-08-3114294023core:UnlistedNon-exchangeTraded2023-08-3114294023core:ShareCapital2023-08-3114294023core:SharePremium2023-08-3114294023core:RevaluationReserve2023-08-3114294023core:OtherReservesSubtotal2023-08-3114294023core:RetainedEarningsAccumulatedLosses2023-08-3114294023core:AfterOneYear2024-09-012025-08-3114294023core:WithinOneYear2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:CostValuation2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-012025-08-3114294023core:Non-currentFinancialInstrumentscore:CostValuation2025-08-3114294023core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-08-3114294023core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3114294023core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3114294023core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3114294023core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3114294023core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3114294023core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3114294023core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3114294023core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3114294023core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3114294023bus:Director12024-09-012025-08-3114294023core:FurnitureFittingsToolsEquipment2024-08-3114294023core:FurnitureFittingsToolsEquipment2025-08-3114294023core:FurnitureFittingsToolsEquipment2024-09-012025-08-31

MONET BEAUTY CLINIC LIMITED

Registered Number
14294023
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2025

MONET BEAUTY CLINIC LIMITED
Company Information
for the year from 1 September 2024 to 31 August 2025

Director

TIAN, Jinkang

Registered Address

56 Maida Vale
London
W9 1PP

Registered Number

14294023 (England and Wales)
MONET BEAUTY CLINIC LIMITED
Statement of Financial Position
31 August 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets3341,835487,861
341,835487,861
Current assets
Stocks442,08042,080
Debtors544,06042,026
Cash at bank and on hand42,283160,208
128,423244,314
Creditors amounts falling due within one year6(1,695,585)(1,668,904)
Net current assets (liabilities)(1,567,162)(1,424,590)
Total assets less current liabilities(1,225,327)(936,729)
Provisions for liabilities8(63,707)(106,837)
Net assets(1,289,034)(1,043,566)
Capital and reserves
Called up share capital100100
Profit and loss account(1,289,134)(1,043,666)
Shareholders' funds(1,289,034)(1,043,566)
The financial statements were approved and authorised for issue by the Board of Directors on 27 May 2026, and are signed on its behalf by:
TIAN, Jinkang
Director
Registered Company No. 14294023
MONET BEAUTY CLINIC LIMITED
Notes to the Financial Statements
for the year ended 31 August 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A, as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Interest income
Interest income is recognised using the effective interest rate method.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible assets are initially measured at cost, and are subsequently measured at cost less any accumulated depreciation and accumulated impairment losses or at a revalued amount. Any tangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

20252024
Average number of employees during the year35
3.Tangible fixed assets

Plant & machinery

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 September 24554,601148,49127,035730,127
At 31 August 25554,601148,49127,035730,127
Depreciation and impairment
At 01 September 24189,68344,4718,112242,266
Charge for year110,92029,6995,407146,026
At 31 August 25300,60374,17013,519388,292
Net book value
At 31 August 25253,99874,32113,516341,835
At 31 August 24364,918104,02018,923487,861
4.Stocks

2025

2024

££
Other stocks42,08042,080
Total42,08042,080
5.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables18,0027,115
Other debtors6,3639,652
Prepayments and accrued income19,69525,259
Total44,06042,026
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables4,0635,571
Bank borrowings and overdrafts36-
Amounts owed to related parties7,9012,994
Other creditors1,680,1161,660,339
Accrued liabilities and deferred income3,469-
Total1,695,5851,668,904
7.Creditors: amounts due after one year
8.Provisions for liabilities

2025

2024

££
Net deferred tax liability (asset)63,707106,837
Total63,707106,837